SKC

● With an aim to take up a share of 30% in the domestic scar care market, the company will strengthen its tissue regeneration business including scar care and stem cell treatments.

SK Bioland (CEO Lee Geun-sik), a subsidiary of SKC, has launched Progel, a next-generation silicone scar care product. Progel is a third-generation product that has improved the weaknesses of previous products and is easy to use.

Silicone scar care products utilize silicon's superior moisture protection feature. Scars are easier to appear in a dry environment. Attaching or applying silicone to a fresh scar helps it healed or reduced by preventing moisture evaporation. Thanks to such property, silicone has been widely used for scar treatment for over 30 years.

However, existing products were inconvenient to use. The first-generation product, which was a sheet form attached to the scar area, was easy to use but did not stick well to curved areas such as the collarbone. The gel-type second-generation product solved this problem but took 5 to 10 minutes until it dries and even then, it would still stain clothes.

SK Bioland's Progel combined the advantages of the first- and second-generation products. It is a gel-type but convenient to use as it dries within five minutes. When it dries, it turns into a film and can be removed easily without leaving remnants.

With the launch of Progel, SK Bioland has solidified its status as a professional regenerative medical company. Currently, SK Bioland sells CollaDerm and CollaHeal Plus collagen, scar care products used for initial wounds. Collagen, one of the skin's components, is a widely-used medical material because it helps regenerate skin. With the addition of Progel, a scar care product, SK Bioland has completed its comprehensive wound care solution.

SK Bioland plans to increase its market share in the domestic scar care market to 30% by 2024. According to internal data, the domestic market was estimated at KRW 30 billion as of 2016. SK Bioland will also advance into overseas markets. After registering with European CE and US FDA this year, the company is gearing up to enter the global scar care market next year. According to a market research agency, the global scar treatment market is estimated to reach KRW 40 trillion by 2025.

An SK Bioland official said, "Within five year, SK Bioland will grow its tissue regeneration business centered on silicon and collagen medical devices and stem cell treatment products into one of its key businesses. We will launch a variety of new regenerative medical care products in an effort to gradually expand the business." [End]